Blis will also have to pay costs, the tribunal said in a decision released yesterday.
The company was fined for breaching NZX continuous disclosure rules.
The company now wants to read any article before it is published.
The censure arose following the company annual meeting on August 19, when Bliss chief executive Barry Richardson became aware the number of pharmacies to which China's largest pharmacy chain Sinopharm would distribute Bliss products was going to increase from 30 to 600.
The same, day Dr Richardson was interviewed by a Fairfax Media journalist.
During the discussion, Dr Richardson said the Sinopharm trial would be increased to up to 600 pharmacies.
On August 20, Blis released an announcement noting it had successfully completed its final audit and was now cleared to export dairy products.
At the time of the announcement, Dr Richardson did not consider the comments he had made about the Sinopharm trial to be material.
On August 24, the Sunday Star Times published an article titled ''Dunedin manufacturer to launch probiotic in Asia''.
The article stated Sinopharm had said it would distribute Blis products in 600 stores in the next few weeks following a successful trial in three stores.
Following discussion, the Blis board noted the article inaccurately stated the trial had been in three stores, rather than 30.
On that basis, the board decided to make an announcement clarifying the position as soon as possible on August 25.
In its submissions to the tribunal, Bliss said the chief executive was caught unprepared by a telephone inquiry.
Normally, direct calls did not go straight through to him but on this occasion, the call did and it caught him unprepared.
He faced a range of questions and the Sinopharm trial was only one of them.
''Changes have been made to ensure no-one will give impromptu interviews and it will be a requirement what is being published is reviewed by Blis first.''
The article was incorrect, giving the reader the impression of an increase by a factor of 200 when it was an increase by 20 times.
That was not the fault of the company, Blis said.
To take the pressure off Dr Richardson, Blis had appointed Tony Offen as executive director in direct response to this incident.
In response, the NZX noted selective disclosure did not need to be deliberate to have a market impact and that was why the test for whether information was ''material'' was an objective test.
''The fact the material information was disclosed by Blis to a Fairfax Media journalist, without being released to NZX at the time, was selective disclosure which caused a market impact.''
The report showed Blis shares opened on August 25 at 2.2c, a 10% rise from the previous day's close of 2c.
The shares last traded at 2.1c, with no trades since Wednesday.
Blis reported an operating loss of $808,000 on turnover of $1.143 million for the six months to September 30.
Turnover increased 59% from the $721,000 reported in the previous corresponding period.
The company has total equity of $5.4 million.
